Navigation Links
Very Soon You can Eat to Your Hearts Content

A new study on mice has raised the hope that it might one day be possible for humans to eat what they want without having to worry about the risk of developing heart disease.

Boffins at the Wake Forest University Baptist Medical Center have successfully deleted a gene in the mice that causes production of ACAT2, an enzyme that alters the molecular structure of cholesterol so that it can be transported to the bodys cells.

Lawrence Rudel, Ph.D., a professor of comparative medicine, said that the study raised hope for humans.

"We deleted an enzyme in mice and they could eat any type of fat and not get heart disease. If youre a mouse, its great. Of course, we dont know yet if it will be the same in humans," he said.

"Regardless of the type of fatty acid in the diet, even trans fat, no atherosclerosis occurs if the ACAT2 enzyme isnt present. Our research in animals tells us that ACAT2 is a potential treatment target to protect people against heart disease," he added.

As a part of the study groups of female mice with and without the ACAT2 gene were fed six different diets enriched with one of these types of fat: fish oil, flax seed oil, polyunsaturated fat from vegetable oil, saturated fat, trans-monounsaturated fat and cis-monounsaturated fat, such as in olive oil.

Fish oil, flax seed oil and polyunsaturated fats are considered "healthy" fats. Saturated fat found in meats, milk and cheeses, coconut oil, palm oil and palm kernel oil is considered a main cause of high cholesterol.

There are two types of monounsaturated fatty acids, "cis" and "trans," which are named according to their shapes. Trans-fatty acids are formed when vegetable oil is treated to make it less likely to go rancid and are found in many fried foods, baked goods and potato chips.

Cis monounsaturated fat is naturally occurring and is particularly high in canola and olive oil.

After 20 weeks on the diets, the mice that had the active ACAT2 enzyme and were fed saturated fat and both types of monounsaturated fat had higher levels of cholesterol and more atherosclerosis than the mice that were fed polyunsaturated fats.

All of the mice without the ACAT2 enzyme were protected against atherosclerosis, which is the buildup of fatty deposits in the blood vessels that can lead to heart attacks and strokes.

"Regardless of the diet fed, the mice without ACAT2 were protected from atherosclerosis," said Rudel.

Eliminating ACAT2 did not interfere with the normal processing of cholesterol. ACAT2 is one of three enzymes that can change cholesterol into a form that can be more easily carried in blood. Studies in both mice and monkeys show that when cholesterol is altered by ACAT2, it is more likely to build up in blood vessel walls and cause atherosclerosis.

Rudel hopes to get funding to repeat the study in monkeys.

"If it works in monkeys, it would be proof of concept that it could work in humans," he said.

He also hopes the research will lead to a drug that can inhibit the enzymes actions in humans. Currently, there is a compound that can block ACAT2, but it must be injected so isnt quite as practical as a drug. He is collaborating with a pharmaceutical company that is working to find a compound that could be taken orally.

Scientists already know that humans produce ACAT2 in the liver and that women have lower levels than men. Research has shown that estrogen can lower ACAT2 production, which may partly explain why women are less likely than men to get heart disease during their estrogen-producing years.

"All of these findings tell us that a potential treatment for protecting against heart disease is a compound that decreases ACAT2 activity," said Rudel.

The findings are reported online by Arteriosclerosis, Thrombosis and Va scular Biology and will appear in a future print issue.


'"/>




Related medicine news :

1. Vitamin E supports Female Hearts
2. Reconstituted Blood Better For Young Hearts
3. A Call To Open Up The Channel Of Goodwill To Rescue The Dying Hearts
4. Surgeons in India to Mend ‘Pakistani Hearts’ by treating 70 Childrn
5. Novel Biological Pacemaker Under Construction for Weak Hearts
6. Murder Accused Wins Hearts By Donating An Eye
7. Heart Brakes: Hearts in European Union Invite Health Attention
8. Apollos Foray into the Hearts of Women
9. Older Donor Hearts worth Its Weight in Gold
10. Stem Cells Of Little Use In Damaged Hearts
11. Rescuing Injured Hearts by Enhancing Regeneration
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance ... assistance to clients in southern Montana, is announcing a focused charity effort to ... The outreach programs offered by Zoo Montana provide students with current knowledge on ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... ... 27, 2017 , ... Excel Medical, the leader in Next-Generation ... of Executive Vice President, Sales and Marketing. Finnegan is a widely known industry ... sales leadership. He has received industry recognition for innovations and new approaches to ...
(Date:6/27/2017)... PA and London UK (PRWEB) , ... June 27, 2017 , ... ... applying to a clinical study is whether they can trust the sponsor to pay ... it is vital that sponsors and CROs establish payment strategies that encourage sites to ...
(Date:6/27/2017)... ... 27, 2017 , ... Salucro, the cloud-based payment platform that ... hospitals and provider groups, has announced that it will now offer Parasail’s payment ... a San Francisco health-finance startup that has launched a series of tech-based products ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)...  Eli Lilly and Company (NYSE: ... Phase 3 MONARCH 2 study showed that abemaciclib, ... combination with fulvestrant, significantly improved progression-free survival (PFS) ... with hormone-receptor-positive (HR+), human epidermal growth factor receptor ... or progressed after endocrine therapy (median PFS, 16.4 ...
(Date:5/30/2017)... May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... today announced that it will be presenting at the 7th annual ... PT. Erez Raphael , CEO, of DarioHealth will be giving ... be held on June 6th & 7th, 2017 at the Luxe ... small / micro-cap space. About ...
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
Breaking Medicine Technology: